Low Incidence of Clean Intermittent Catheterisation With OnabotulinumtoxinA in Diverse Age Groups of Overactive Bladder Patients With Corresponding Improvements in Urinary Symptoms, Treatment Response, and Quality of Life

Nitti V1, Drake M2, Everaert K3, Rovner E4, Dmochowski R5, Ginsberg D6, Radomski S7, Aboushwareb T8, Chang C9, Chapple C10

Research Type

Clinical

Abstract Category

Overactive Bladder

Abstract 313
Female Pelvic Floor 3
Scientific Podium Short Oral Session 18
Wednesday 13th September 2017
17:22 - 17:30
Spadolini F
Overactive Bladder Clinical Trial Incontinence Detrusor Overactivity Quality of Life (QoL)
1. New York University Langone Medical Center, New York, NY, USA, 2. Bristol Urological Institute, Bristol, UK, 3. Ghent University Hospital, Ghent, Belgium, 4. Medical University of South Carolina, Charleston, SC, USA, 5. Vanderbilt University Medical Center, Nashville, TN, USA, 6. USC Institute of Urology, Los Angeles, CA, USA, 7. University of Toronto, Toronto, Canada, 8. Allergan plc, Irvine, CA, USA, 9. Allergan plc, Bridgewater, NJ, USA, 10. The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, UK
Presenter
V

Victor Nitti

Links

Abstract

28/03/2024 01:54:29